<br>        Inclusion Criteria:<br><br>          -  The patient has given written informed consent prior to any study related procedures<br><br>          -  The patient is male or female and is aged between 18 and 75 years, inclusive,<br><br>          -  Diagnosis of acromegaly defined by i) GH nadir > 1 ng/mL as assessed by an oral<br>             glucose tolerance test for non diabetic patients (central laboratory results) or a<br>             mean GH level > 1 ng/mL based on 5 samples taken every 10 to 15 minutes for diabetic<br>             patients ( central laboratory results) AND ii) IGF-1 concentrations elevated above the<br>             age- and sex-matched normal range for diabetic and non diabetic patients (central<br>             laboratory results),<br><br>          -  The patient has a pituitary adenoma with a diameter greater than or equal to 10 mm<br>             based on Magnetic Resonance Imaging (MRI) central reading,<br><br>          -  The patient has no visual field defect identified at the visual evaluation, performed<br>             by Goldman Visual Fields Analyser and Automated visual field static perimeter, except<br>             visual field abnormality at the time of screening and that is in the investigator's<br>             Clinical judgement:<br><br>               -  Not related to the pituitary adenoma<br><br>               -  Clinically stable condition not presumed to change during the study period<br><br>               -  Not modifying the ability to evaluate visual field changes related to the<br>                  macroadenoma<br><br>        Exclusion Criteria:<br><br>          -  The patient has a history of hypersensitivity to Lanreotide or drugs with a similar<br>             chemical structure,<br><br>          -  The patient has received any unlicensed drug within the 30 days prior to the screening<br>             visit or is scheduled to receive an unlicensed drug during the course of the study,<br><br>          -  The patient is likely to require treatment during the study with somatostatin<br>             analogues other than Lanreotide Autogel 120 mg, dopamine agonist, GH receptor<br>             antagonist (pegvisomant), and Cyclosporine or drugs that are not permitted by the<br>             study protocol,<br><br>          -  The patient is a female at risk of pregnancy during the study and is not using<br>             acceptable contraceptive methods. Females of childbearing potential must provide a<br>             negative pregnancy test at start of study and must be using oral, double barrier<br>             (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide;<br>             or male condom and diaphragm with spermicide), injectable contraception or an intra<br>             uterine device. Non childbearing potential is defined as post-menopause for at least 1<br>             year, surgical sterilisation or hysterectomy at least three months before the start of<br>             the study,<br><br>          -  The patient is pregnant or lactating,<br><br>          -  The patient has a history of, or known current, problems with alcohol abuse,<br><br>          -  The patient has any mental condition rendering the patient unable to understand the<br>             nature, scope and possible consequences of the study, and/or evidence of an<br>             uncooperative attitude.<br><br>          -  The patient has abnormal baseline findings, any other medical condition(s) or<br>             laboratory findings that, in the opinion of the Investigator, might jeopardize the<br>             patient's safety or decrease the chance of obtaining satisfactory data needed to<br>             achieve the objective(s) of the study,<br><br>          -  The patient has undergone pituitary surgery or pituitary radiotherapy prior to study<br>             entry,<br><br>          -  The patient has previously been treated with a somatostatin analogue,<br><br>          -  The patient has received a dopamine agonist or a GH receptor antagonist (pegvisomant)<br>             prior to study entry,<br><br>          -  The patient is expected to require pituitary surgery (adenomectomy) or to receive<br>             radiotherapy during the study period,<br><br>          -  Patients with suspected associated prolactinoma: prolactin level > 100 ng/mL (central<br>             laboratory results),<br><br>          -  Patient is allergic to Gadolinium (MRI contrast agent) or has acute or chronic severe<br>             renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2),<br><br>          -  Patient known by Investigator, to have congenital or acquired optic nerve disease or<br>             any visual abnormality with risk of worsening during the course of the study (e.g<br>             glaucoma), influencing ability to evaluate Visual Field changes related to the<br>             macroadenoma.<br>